RecruitingPhase 2NCT07548177
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
Studying Alveolar soft tissue sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- Benmelstobart injection combined with Anlotinib hydrochloride capsule(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 14 years · All sexes
- Timeline
- 2026 – 2028
Study locations (15)
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Army Medical University of the People's Liberation Army of China, Chongqing, Chongqing Municipality, China
- Sun Yat-sen University Cancer Center, Guangdong, Guangdong, China
- Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Xiangya Hospital of Central South University, Changsha, Hunan, China
- The first hospital of Jilin University, Changchun, Jilin, China
- Shandong First Medical University Affiliated Tumor Hospital, Jinan, Shandong, China
- Shanghai General Hospital, Shanghai, Shanghai Municipality, China
- West China Hospital of Sichuan University, Chengdu, Sichuan, China
- Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality, China
- Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi, Xinjiang, China
- The Second Affiliated Hospital, Zhejiang University School of Medicine., Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07548177 on ClinicalTrials.govOther trials for Alveolar soft tissue sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06066138A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06813417CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part SarcomaUniversity of Calgary
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06789081GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)AHS Cancer Control Alberta
- RECRUITINGPHASE2NCT05333458Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM TrialNational Cancer Institute (NCI)
- RECRUITINGNANCT03967834Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma GroupInstitut Claudius Regaud
- RECRUITINGPHASE2NCT04332874A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT03016819Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)Advenchen Laboratories, LLC
- ACTIVE NOT RECRUITINGPHASE2NCT03141684Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaNational Cancer Institute (NCI)